PARP1 and small cell lung carcinoma: In addition to PARP inhibitors, this analysis revealed greater resistance of mesenchymal SCLC to alkylating agents, TOP2A/B inhibitors, BCL2 inhibitors, IGF1R inhibitors, and HDAC1 inhibitors.